Research ArticleClinical Investigation
111In-Labeled EGF Is Selectively Radiotoxic to Human Breast Cancer Cells Overexpressing EGFR
Raymond M. Reilly, Reza Kiarash, Ross G. Cameron, Nicole Porlier, Jasbir Sandhu, Richard P. Hill, Katherine Vallis, Aaron Hendler and Jean Gariépy
Journal of Nuclear Medicine March 2000, 41 (3) 429-438;
Raymond M. Reilly
Reza Kiarash
Ross G. Cameron
Nicole Porlier
Jasbir Sandhu
Richard P. Hill
Katherine Vallis
Aaron Hendler


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
111In-Labeled EGF Is Selectively Radiotoxic to Human Breast Cancer Cells Overexpressing EGFR
Raymond M. Reilly, Reza Kiarash, Ross G. Cameron, Nicole Porlier, Jasbir Sandhu, Richard P. Hill, Katherine Vallis, Aaron Hendler, Jean Gariépy
Journal of Nuclear Medicine Mar 2000, 41 (3) 429-438;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Targeting Micrometastases: The Effect of Heterogeneous Radionuclide Distribution on Tumor Control Probability
- Molecular Radiotherapy Using Cleavable Radioimmunoconjugates That Target EGFR and {gamma}H2AX
- ErbB-2 Blockade and Prenyltransferase Inhibition Alter Epidermal Growth Factor and Epidermal Growth Factor Receptor Trafficking and Enhance 111In-DTPA-hEGF Auger Electron Radiation Therapy
- Cellular Dosimetry of 111In Using Monte Carlo N-Particle Computer Code: Comparison with Analytic Methods and Correlation with In Vitro Cytotoxicity
- Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy
- Targeted In vivo Imaging of Integrin {alpha}v{beta}6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model
- In Vivo SPECT Quantification of Transplanted Cell Survival After Engraftment Using 111In-Tropolone in Infarcted Canine Myocardium
- Relationship Between Induction of Phosphorylated H2AX and Survival in Breast Cancer Cells Exposed to 111In-DTPA-hEGF
- Imaging Epidermal Growth Factor Receptor Expression In vivo: Pharmacokinetic and Biodistribution Characterization of a Bioconjugated Quantum Dot Nanoprobe
- Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor
- 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer
- Carbon Nanotubes: Potential Benefits and Risks of Nanotechnology in Nuclear Medicine
- [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 Is a Highly Efficient Radiotherapeutic for Glucagon-Like Peptide-1 Receptor-Targeted Therapy for Insulinoma
- Preclinical Pharmacokinetic, Biodistribution, Toxicology, and Dosimetry Studies of 111In-DTPA-Human Epidermal Growth Factor: An Auger Electron-Emitting Radiotherapeutic Agent for Epidermal Growth Factor Receptor-Positive Breast Cancer
- Auger Electrons: Lethal, Low Energy, and Coming Soon to a Tumor Cell Nucleus Near You
- A Kit Formulated Under Good Manufacturing Practices for Labeling Human Epidermal Growth Factor with 111In for Radiotherapeutic Applications
- Antitumor Effects and Normal Tissue Toxicity of 111In-Labeled Epidermal Growth Factor Administered to Athymic Mice Bearing Epidermal Growth Factor Receptor-Positive Human Breast Cancer Xenografts
- Cancer Therapy with Auger Electrons: Are We Almost There?